As per the outcomes that Glenmark offered to the regulator, the research confirmed no superior medical outcomes with the addition of Umifenovir, it added.
This was the second medical research after the profitable Favipiravir monotherapy trial earlier this yr that led the corporate to receiving the Emergency Use Authorisation for Favipiravir, Glenmark mentioned.
“These newest findings verify that the addition of Umifenovir doesn’t present any incremental profit in medical outcomes. Thus Favipiravir remedy together with supportive care stays an appropriate and efficient alternative for gentle to average COVID-19 an infection,” Monika Tandon Senior VP & Head, Scientific Growth, International Specialty/Branded Portfolio, Glenmark Prescribed drugs mentioned. AKT BAL BAL